AIM
EBS icon

Aigen Investment Management’s Emergent Biosolutions EBS Stock Holding History

Aigen Investment Management’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-16,262
Closed -$1.46M – 683
2020
Q4 		$1.46M Buy
+16,262
New +$1.49M 0.19% 138
2020
Q2 		– Sell
-8,775
Closed -$508K – 942
2020
Q1 		$508K Buy
8,775
+8,175
+1,363% +$471K 0.07% 416
2019
Q4 		$32K Buy
+600
New +$32.5K 0.01% 860

Other funds holding EBS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
Manulife (Manufacturers Life Insurance)
Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Aigen Investment Management's EBS Position: Q1 2021 in Review

Aigen Investment Management sold out of Emergent Biosolutions (EBS) in Q1 2021, closing a stake of 16,262 shares — an estimated $1.46M sold.

Aigen Investment Management first reported a position in EBS in Q4 2019 and held it in 3 quarters. The position peaked at $1.46M in Q4 2020. 340 funds tracked by Wall St. Rank hold EBS as of Q1 2021.

  • Aigen Investment Management reported no remaining Emergent Biosolutions position as of Q1 2021 after selling out during the quarter.
  • Aigen Investment Management sold 16,262 Emergent Biosolutions shares in Q1 2021, an estimated $1.46M.
  • Aigen Investment Management first reported a position in Emergent Biosolutions in Q4 2019 and held it in 3 quarters.
  • Aigen Investment Management's Emergent Biosolutions position peaked at $1.46M in Q4 2020.
  • 340 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q1 2021.

Based on Aigen Investment Management's 13F filing for Q1 2021, filed 11 May 2021.